Form 4: Rocket Pharmaceuticals Executive Sells Shares to Cover Tax Obligations

Kinnari Patel, President, Head of R&D and Chief Operating Officer of Rocket Pharmaceuticals, sold 6,078 shares of common stock to cover tax obligations related to vesting Restricted Stock Units.

Summary

• Kinnari Patel, an executive at Rocket Pharmaceuticals, sold 6,078 shares of common stock on February 21, 2025, at a price of $10.58 per share.
• The sale was executed to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).
• Following the transaction, Patel directly owns 444,103 shares of common stock.
• Patel also indirectly owns 5,675 shares through her spouse and 104,927 shares through Adaptive Technology LLC, a limited liability company managed by her husband.

Sentiment

Score: 5

Explanation: Neutral sentiment as the filing relates to a routine transaction for tax purposes and doesn't indicate a significant change in the executive's confidence in the company.

Industry Context

This is a routine Form 4 filing, reflecting an insider transaction related to tax obligations. Such filings are common and provide transparency into the trading activities of company executives.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.

Key Dates